Ligandrol LGD-4033

5mg per capsule · 90 capsules

£49.99

In stock · Order before 2pm for next-day dispatch

Purity≥99% (HPLC verified)

Active ingredient5mg per capsule

Count90 capsules

ManufacturerUK — ISO certified

Overall research score

8.7 / 10

Excellent · Most potent SARM for lean mass development

Metric breakdown

Anabolic potency 9.5

Muscle preservation 9.2

Safety profile 7.2

Bioavailability 8.0

Research depth 8.5

Suppression risk Low

Hepatotoxicity Minimal

Compound profile

Chemical name: 4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-methylethylamino]-1-(4-fluorophenyl)ethyl]-2-(trifluoromethyl)benzonitrile
Molecular weight: 338.25 g/mol
Half-life: 24–36 hours
Detection time: Up to 3 weeks
Research active: 5–10mg / day
Research cycle: 8–12 weeks
CAS number: 1165910-22-4

Research applications

Lean mass gains Strength Muscle preservation Recomposition PCT required

Research use only. Scores derived from published preclinical and peer-reviewed literature. Not intended for human consumption.

Description

What Is LGD-4033 (Ligandrol)?

LGD-4033 (Ligandrol) is an investigational compound studied in androgen receptor pathway research. This page provides a practical research reference overview with mechanism context, evidence limits, handling notes, and batch verification standards.

Compound Profile

Name	LGD-4033 (Ligandrol)
CAS	1165910-22-4
Formula	C14H12F6N2O
Molecular Weight	338.25 g/mol
Category	Investigational non-steroidal AR-active compound
PubChem	44137675

What is lgd-4033 ligandrol is a common query used by researchers comparing AR-pathway references and trial-history summaries.

How Does LGD-4033 Work?

Published work describes LGD-4033 as an androgen receptor ligand studied for selective pathway behaviour in preclinical and early clinical settings. This page is technical reference content, not therapeutic guidance.

Researchers often compare lgd-4033 vs rad-140 research when assessing selectivity models, endpoint design, and evidence maturity.

What Does Current Research Say?

Clinical and preclinical literature includes body-composition and endocrine endpoint discussions.
Evidence quality varies by cohort, duration, and endpoint type.
No broad consumer therapeutic approval exists.
Interpretation should prioritize study design and method quality.

Typical search intent includes lgd-4033 dosage research use and lgd-4033 cycle length research phrasing, which should be read as literature context rather than user instruction.